In today’s recent session, 0.83 million shares of the Abivax ADR (NASDAQ:ABVX) have been traded, and its beta is 2.87. Most recently the company’s share price was $68.1, and it changed around $1.61 or 2.42% from the last close, which brings the market valuation of the company to $4.32B. ABVX at last check was trading at a discount to its 52-week high of $72.90, offering almost -7.05% off that amount. The share price’s 52-week low was $4.77, which indicates that the recent value has risen by an impressive 93.0% since then. We note from Abivax ADR’s average daily trading volume that its 10-day average is 5.19 million shares, with the 3-month average coming to 1.05 million.
Abivax ADR stock received a consensus recommendation rating of Buy, based on a mean score of 1.00. If we narrow it down even further, the data shows that 0 out of 9 analysts rate the stock as a Sell; another 4 rate it as Overweight. Among the rest, 1 recommended ABVX as a Hold, whereas 4 deemed it a Buy, and 0 rated it as Underweight.
Abivax ADR (NASDAQ:ABVX) trade information
Instantly ABVX has been showing a green trend so far today with a performance of 2.42% on intraday trading today. The performance over the last five days has remained in the green territory. The rise to weekly highs of 72.90 on recent trading dayincreased the stock’s daily price by 6.58%. The company’s shares are currently up 474.66% year-to-date, but still up 571.57% over the last five days. On the other hand, Abivax ADR (NASDAQ:ABVX) is 848.43% up in the 30-day period. We can see from the shorts that 1.43 million shares have been sold at a short interest cover period of 3.64 day(s).
The consensus price target as assigned by Wall Street analysts is $33, which translates to bulls needing to decrease their stock price by -106.36% from its current value. Analyst projections state that ABVX is forecast to be at a low of $12 and a high of $74.
Looking at the company’s year-over-year earnings, the past five years showed a negative earnings growth rate of -1.44%. Abivax ADR earnings are expected to increase by -1.52% in 2025, but the outlook is positive 4.70% per year for the next five years.
ABVX Dividends
Abivax ADR’s next quarterly earnings report is expected to be released on 2025-Mar-24.
Abivax ADR (NASDAQ:ABVX)’s Major holders
Upon looking at major shareholders, 43.26% of them are in the hands of institutional investors. The stock currently has a share float of 43.26%. Abivax ADR stock is held by 49.0 institutions, with TCG CROSSOVER MANAGEMENT, LLC being the largest institutional investor. By 2024-06-30, it held 14.0635% of the shares, which is about 6.06 million shares worth $80.07 million.
DEEP TRACK CAPITAL, LP, with 9.7055% or 4.18 million shares worth $55.26 million as of 2024-06-30, holds the second largest percentage of outstanding shares.
